Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance
Wah Academia Journal of Health and Nutrition · 30.06.2026 · 2 (2) · 27-35
DOI: 10.63954/bantev40 ↗Kurz gefasst
Fachartikel in der Zeitschrift Wah Academia Journal of Health and Nutrition, online erschienen am 30.06.2026. Verfasst von Aamir Ajmal und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Healthcare-associated (HA) infections caused by methicillin-resistant Staphylococcus aureus (MRSA) continue to be a big problem worldwide. The mecA gene is responsible for the production of PBP2a which is responsible for the resistance to all beta-lactam antibiotics. There are currently very little alternative therapeutic options as the treatment is becoming limited. The advantage of CRISPR-Cas9 technology lies in the ability to target genes with precision, however, there are technical delivery challenges in the application of this technology in bacterial pathogens.
Objective
The aim of this study was to assess the efficacy of CRISPR-Cas9 delivery by liposomes with Lipofectamine and its ability to knock out the mecA gene in MRSA and make them susceptible to beta-lactam antibiotics.
Methods
MO of MRSA ATCC 43300 was electroporated with a Cas9-sgRNA RNP complex using Lipofectamine CRISPRMAX with a mecA-targeting guide sgRNA designed using CHOPCHOP. An antibacterial activity was determined (CFU, growth curves, biofilm), gene targeting (PCR, Sanger sequencing), resistance reversal (MIC, disk diffusion) and safety (MTT, hemolysis). All experiments were repeated three times (n=3), data presented as mean ± SD and analyzed by One Way Analysis of Variance (ANOVA) with Tukey's post hoc test (p
Zitieren
APA
Ajmal, A., Fasiha, Gharsheen, H. K., Ali, M. A., Saleem, R., Saleem, M. S., Sajid, M. F., Tariq, A., Noor, A., & Siyal, T. (2026). Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance. Wah Academia Journal of Health and Nutrition, 2(2), 27-35. https://doi.org/10.63954/bantev40
Vancouver
Ajmal A, Fasiha, Gharsheen HK, Ali MA, Saleem R, Saleem MS, et al. Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance. Wah Academia Journal of Health and Nutrition. 2026;2(2):27-35. doi:10.63954/bantev40
BibTeX
@article{Ajmal2026,
author = {Ajmal, Aamir and Fasiha and Gharsheen, Hafiza Kainat and Ali, Muhammad Amjad and Saleem, Rida and Saleem, Muhammad Shahbaz and Sajid, Muhammad Faizan and Tariq, Amina and Noor, Amna and Siyal, Tahseen},
title = {Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance},
journal = {Wah Academia Journal of Health and Nutrition},
year = {2026},
volume = {2},
number = {2},
pages = {27--35},
doi = {10.63954/bantev40}
}
EUVIMED